Casaasdas

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Por um escritor misterioso
Last updated 17 abril 2025
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
PDF) Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
The proportions of patients in ASAS20 response (A), ASAS40 response
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study, Arthritis Research & Therapy
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Baseline characteristics of patients included in the two treatment arms
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Changes from baseline in ASDAS and BASFI over time. Dashed line: all
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Baseline characteristics of ASDAS ID and ASAS PR responders and
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
ASDAS calculator - ASAS
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Frontiers Targeted Therapies in Axial Psoriatic Arthritis
Recomendado para você
você pode gostar

© 2014-2025 renovateindia.wappzo.com. All rights reserved.